1. Generics Bulletin
  2. >>Legal & IP

Accord And Aspire Beat Bimatoprost Patent In The UK

 
• By Aidan Fry

Accord and Aspire have knocked down a patent barrier to bringing bimatoprost 0.1mg/ml to the UK market by convincing a Patent Court judge that the claimed formulation was obvious.

Eye drops
A patent barrier to generic bimatoprost 0.01% eye drops has been knocked down by the UK Patents Court • Source: Shutterstock

Accord Healthcare and Aspire Pharma have convinced the UK Patents Court that a patent protecting 0.1mg/ml ophthalmic formulations of bimatoprost until March 2026 is invalid as obvious. Both Accord and Aspire have obtained marketing authorizations to offer generic versions of Allergan’s Lumigan 0.1mg/ml glaucoma treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.